NCT01546415View on ClinicalTrials.gov

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Iron Overload
Interventions
DRUG

Desferasirox

Initial Dose: 20 mg/kg/d. Dose modification according to protocol.

Trial Locations (7)

200437

Novartis Investigative Site, Shanghai

300020

Novartis Investigative Site, Tianjin

610041

Novartis Investigative Site, Chengdu

Unknown

Novartis Investigative Site, Beijing

Novartis Investigative Site, Chengdu

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Tianjin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY